Clinical Trials Logo

Pancreas Adenocarcinoma clinical trials

View clinical trials related to Pancreas Adenocarcinoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT06090318 Withdrawn - Gastric Cancer Clinical Trials

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Start date: May 19, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, single-arm, Phase 1b/2 study designed to evaluate the safety, tolerability, and preliminary efficacy of milademetan in combination with atezolizumab in patients with advanced solid tumors with confirmed homozygous CDKN2A loss and WT TP53 who have progressed on or are refractory to prior PD-1/PD-L1 inhibitor therapy and who, in the opinion of the Investigator, are unlikely to tolerate or derive clinically meaningful benefit from other therapy. This study will determine the recommended dose of milademetan when given in combination with atezolizumab (the combination RP2D) using a dose de-escalation safety assessment cohort (Phase 1b). Following identification of the combination RP2D, the safety profile and preliminary anti-tumor activity of the combination RP2D will be evaluated in a larger population in a dose expansion cohort (Phase 2).

NCT ID: NCT04821219 Withdrawn - Clinical trials for Pancreas Adenocarcinoma

Personalized Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

This study is designed to prospectively investigate the feasibility of establishing patient-derived tumoroids (PDT) as a platform for a personalized approach for response prediction and guide optimal neoadjuvant and/or adjuvant approach. PDT will be investigated to determine drug sensitivity, predict the response to chemotherapy agents and radiation therapy, and validate this response in treated patients, and to establish the feasibility of PDT as a platform for a personalized approach to guide multimodality treatment.

NCT ID: NCT04045730 Withdrawn - Clinical trials for Pancreas Adenocarcinoma

The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.

Start date: November 15, 2019
Phase: Phase 2
Study type: Interventional

This is an open-label single arm phase 2 study for patients with metastatic pancreatic ductal adenocarcinoma who have not received any prior systemic therapies.